Amiloride in MS
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Amiloride
What it measured
Main measures
MRI evidence of slowing of progression. However the study will terminate at 52 weeks after patients have been started on study drug
MRI lesions
Who could take part
Progressive MS
Inclusion: 1. Subjects with primary progressive MS, who have completed the Phase I of the study which was performed over 52 weeks, when patients were not given any specific treatment. Exclusion: 11. Any immunosuppressive or immunomodulatory therapy received in the previous 12 months of the study.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The prinicipal aim of this study is to assess the efficacy of Amiloride on neurodegenerative change in multiple sclerosis.The primary outcome measure will be change in Magnetic resonance imaging markers studied over a period of 12 months.
Loading reviews and guidelines…
Related trials
- MS-SMART
Phase 2 · Completed
Missed its main goal
- FLUOX-PMS
Phase 4 · Completed
Result in a paper, not read yet
- EPO-ProgMS
Phase 2 · Status unknown
No result found
- A pilot single-centre randomised controlled trial of reco…
Phase 2 · Stopped early
Stopped early
- Single Oral Doses Study of Nerispirdine on Visual Functio…
Phase 2 · Completed
No result found
- Fluoxetine in progressive multiple sclerosis: a placebo-c…
Completed (inferred)
Result in a paper, not read yet
History
Started
Jul 2008
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error